Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04400331 |
Recruitment Status :
Active, not recruiting
First Posted : May 22, 2020
Last Update Posted : November 2, 2023
|
Sponsor:
Neurocrine Biosciences
Collaborator:
Huntington Study Group
Information provided by (Responsible Party):
Neurocrine Biosciences
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | December 2023 |
Estimated Study Completion Date : | December 2023 |